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doi:10.1016/j.ejvs.2011.08.009Abstract Objective and design: The role of Thoracic Endovascular Repair (TEVAR) in chronic
type B aortic dissection remains controversial and its mid-term success as an alternative to open
repair or best medical therapy remains unknown. The aim of the present study was to provide
a systematic review of mid-term outcomes of TEVAR for chronic type B aortic dissection.
Materials and methods: Medline, trial registries, conference proceedings and article reference
lists from 1950 to January 2011 were searched to identify case series reporting mid-term
outcomes of TEVAR in chronic type B dissection. Data were extracted for review.
Results: 17 studies of 567 patients were reviewed. The technical success rate was 89.9% (range
77.6e100). Mid-term mortality was 9.2% (46/499) and survival ranged from 59.1 to 100% in
studies with a median follow-up of 24 months. 8.1% of patients (25/309) developed endoleak,
predominantly type I. Re-intervention rates ranged from 0 to 60% in studies with a median
follow-up of 31 months. 7.8% of patients (26/332) developed aneurysms of the distal aorta or
continued false lumen perfusion with aneurysmal dilatation. Rare complications included de-
layed retrograde type A dissection (0.67%), aorto-oesophageal fistula (0.22%) and neurological
complications (paraplegia 2/447, 0.45%; stroke 7/475, 1.5%).
Conclusion: The absolute benefit of TEVAR over alternative treatments for chronic B-AD remains
uncertain. The lack of natural history data formedically treated cases, significant heterogeneity
in case selection and absence of consensus reporting standards for intervention are significanteducation questions on this paper, please go to www.vasculareducation.com and click on ‘CME’
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TEVAR for Chronic Type B Aortic Dissection 633Figobstructions to interpreting the mid-term data. High-quality data from registries and clinical
trials are required to address these challenges.
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The role of thoracic endovascular aortic repair (TEVAR) in
complicated chronic type B aortic dissection (B-AD) remains
controversial.1e5 A recent expert consensus document
concluded that medical therapy remains the best treat-
ment for uncomplicated chronic B-AD.6 This was supported
by the INSTEAD (INvestigation of STEnt grafts in patients
with type B Aortic Dissection) trial, which randomised
patients with uncomplicated chronic B-AD to TEVAR with
best medical therapy or to best medical therapy alone. The
trial revealed no advantages in the rates of survival, aortic
rupture or need for re-intervention of TEVAR over medical
therapy at 2 years.7
Intervention is justified in complicated chronic B-AD; in
patients with significant aortic dilatation (maximum
thoracic aortic diameter >5.5 mm), rapid aortic growth
(>1 cm/year), the development of unrelenting pain,
uncontrollable hypertension, end-organ ischaemia or aortic
rupture.6,8 In these settings, TEVAR aims to prevent
persistent perfusion of the false lumen (FL) with the
resultant aortic expansion (estimated at 1e4.3 mm/year),
which has been shown to increase the risk of aortic ruptureure 1 PRISMA flow diagram dand other complications.8,9 Once the aortic diameter
exceeds 60 mm, the risk of FL rupture is estimated at 30%
per annum.10,11
The appropriateness of TEVAR for chronic dissection has
been questioned due to the established nature of the false
lumen and the presence of multiple fenestrations that
decrease the likelihood of complete FL thrombosis.6 Other
areas of uncertainty include the length of aortic coverage
required to accomplish successful treatment. Although
favourable perioperative outcomes and one-year survival
rates have been demonstrated for TEVAR compared to open
surgery, the long-term outcomes of TEVAR remain
unknown.12 The outcomes of TEVAR have been reported in
mixed pathology comprising both acute and chronic
dissections,13,14 as well as exclusively for acute type B
dissection,15 but few separate data exist to define the
performance of TEVAR exclusively in the setting of chronic
type B dissection. This is despite evidence that acute B-AD
and chronic B-AD behave differently following endovascular
intervention and consequently have different outcomes.13
Furthermore, those dissections with a strong genetic aeti-
ology may have different outcomes to those with a degen-
erative aetiology.16epicting search strategy used.
Table 1 Case selection.
Study Duration Type N Age (years) Male Indication Symptomatic
presentation
Symptom onset
to repair
(months)
Emergency
Xu 20102 2001e2007 retrospective
cohort
84 mean
53.3  11.6
(32e78)
69/84
(82.1%)
61/84 (72.6%) back pain,
3/84 (3.6%) shock
64/84 (76.2%) 13.9  22
(1e120)
3/84 (3.6%)
Czerny
20105
2004e2009 retrospective
cohort
14 median 63 11/14
(78.6%)
aortic diameter Z >60 mm e 19 (4e84) e
Nienaber
20097
2003e2005 randomised
controlled trial
72 mean
60.3  10.7
62/72
(86.1%)
aortic diameter <60 mm 17/72 (23.6%) 1.7 (0.63e9.37) e
Manning
200920
2000e2006 retrospective
cohort
10 mean 63
(45e79)
8/10
(80.0%)
FL enlargement e 16 (2e71) 0
Kim 20094 1994e2007 retrospective
cohort
72 mean
55  12
65/72
(90.3%)
aortic diameter >60 mm,
aortic enlargement >5 mm
per year, continuous FL
leakage, refractory pain,
dynamic obstruction
e e e
Guangqi
200921
2001e2006 retrospective
cohort
49 mean
57.1  10
46/49
(93.9%)
aortic diameter >50 mm,
aortic enlargement >5 mm
per year, acute symptoms
e e e
Alves 200922 1997e2004 retrospective
cohort
61 mean
56.4  10.8
47/61
(77.0%)
aortic diameter >55 mm,
persistent pain, diagnosed or
imminent rupture, organ or
limb ischaemia
15/61 (24.6%) 10.5  18 2/61 (3.3%)
Sayer 200823 2000e2007 prospective
cohort
40 mean
66.6  11.9
26/40
(65.0%)
aortic diameter >55 mm,
aortic enlargement >10 mm
in 6 months, aortic rupture,
refractory chest pain,
end-organ ischaemia
e e e
Marcheix
200824
1996e2004 retrospective
cohort
15 mean
40  12
(22e61)
11/15
(73.3%)
aortic diameter >40 mm,
aortic enlargement >5 mm
in 6 months
e e 1/15 (6.6%)
Jing 200825 2002e2007 retrospective
cohort
35 mean
69  12.7
30/35
(85.7%)
aortic diameter >50 mm,
aortic enlargement >1 mm
per year, aortic rupture,
refractory chest pain,
refractory hypertension,
branch vessel ischaemia
2/35 (5.7%) e e
Song 200626 1999e2005 retrospective
cohort
17 mean
64  14
(35e88)
10/17
(58.8%)
10/17 (58.8%) aneurysmal
enlargement, 6/17 (35.3%)
chest pain, 4/17 (23.5%)
dissection progression,
1/17 (5.8%) rupture,
1/17 (5.8%) visceral/
peripheral ischaemia
e e 1/17
(5.9%)
Bockler
200627
1997e2004 prospective
cohort
14 mean 58
(30e82)
11/14
(78.6%)
1/14 (7.1%) renal/visceral
ischaemia, 7/14 (50.0%)
imminent rupture, 1/14
(7.1%) aorto-bronchial fistula
e e 0
Kusagawa
200528
1997e2003 retrospective
cohort
17 mean
59.4  12.9
13/17
(76.5%)
aortic diameter >50 mm e e e
Eggebrecht
200529
1999e2004 retrospective
cohort
28 mean
62.2  10.8
(36e83)
24/28
(85.7%)
aortic diameter >50 mm,
aortic enlargement >1 mm
per year, contained rupture,
refractory chest pain,
refractory hypertension,
branch vessel ischaemia
e e 0
Shimono
200230
1997e2000 retrospective
cohort
13 mean
60.3  14.1
10/13
(76.9%)
aortic diameter >50 mm 1/13 (7.7%) e 0
Kato 200231 1997e2001 retrospective
cohort
14 mean
61  14
(38e82)
12/14
(85.7%)
aortic diameter >50 mm e 35  94 0
Herold
200232
1999e2001 retrospective
cohort
12 mean
68.6
(58e84)
10/12
(83.3%)
3/12 (25.0%) FL
enlargement >20 mm in 3
months, 7/12 (58.3%) TL
collapse, 2/12 (16.7%)
refractory chest pain
12/12 (100%) e 1/12
(8.3%)
Total 567 465/567 e 111/277 e 8/268
Average 59.8 years 82.0% e 40.1% 18 months
(0.63e129)
3.0%
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Maximum
descending aortic
diameter (mm)
Prior aortic
surgery
Marfan’s Hypertension Diabetes mellitus Coronary artery
disease
Chronic renal
impairment
Chronic respiratory
impairment
mean 58.1  9.8
(45e80)
e 1/84 (1.2%) 67/84 (79.8%) 9/84 (10.7%) e e e
median 60
(50e100)
2/14 (14.3%) 0 14/14 (100%) e e e e
mean 44.1  9.6 e 0 61/72 (84.7%) 5/72 (6.9%) e e 7/72 (9.7%)
e 1/10 (10.0%) e e e e e e
e 3/72 (4.2%) 2/72 (2.8%) 67/72 (93.1%) 10/72 (13.9%) 12/72 (16.7%) 4/72 (5.6%) e
e e 1/49 (2.0%) 47/49 (95.9%) e e 3/49 (6.1%) e
mean 59  12 e 0 23/61 (37.7%) 2/61 (3.3%) e 9/61 (14.8%) e
e 11/40 (27.5%) 7/40 (17.5%) 33/40 (82.5%) 4/40 (10.0%) 12/40 (30%) 15/40 (37.5%) 6/40 (15.0%)
mean 61.3  24.7 11/15 (73.3%) 15/15 (100%) 7/15 (46.7%) 1/15 (6.67%) e 5/15 (3.33%) 6/15 (40.0%)
mean FL diameter
65.4  14.8 mm,
mean TL diameter
13.8  10.2 mm
e 0 30/35 (85.7%) 9/35 (25.7%) 4/35 (11.4%) 2/35 (5.7%) 4/25 (11.4%)
50.7  14 2/17 (11.8%) 0 16/17 (94.1%) 2/17 (11.8%) 2/17 (11.8%) 5/17 (29.4%) 5/17 (29.4%)
e 2/14 (14.3%) e e e e e e
mean 46.4 3/17 (17.6%) 0 11/17 (64.7%) e e e e
e 6/28 (21.4%) e 27/28 (96.4%) 4/28 (14.3%) 10/28 (35.7%) 10/28 (35.7%) 5/28 (17.9%)
e 3/13 (23.1%) e 8/13 (61.5%) 2/13 (15.4%) e 0 e
e 3/14 (21.4%) e 9/14 (64.3%) e 1/14 (7.1%) 0 e
mean
61.2  15
(41e134)
e e 11/12 (91.7%) 1/12 (8.3%) 4/12 (33.3%) e 5/12 (41.6%)
e 47/254 26/476 431/543 49/449 45/218 53/344 38/209
55.1 mm
(34.5e134)
18.5% 5.5% 79.4% 10.9% 20.6% 15.4% 18.2%
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636 S.G. Thrumurthy et al.The mid-term outcomes of TEVAR in chronic B-AD are
critical to understanding the success of treatment in
a disease process that continues to evolve even after surgical
or endovascular intervention. The aim of the present study
was to provide the first focussed systematic review of mid-
term outcomes of TEVAR for chronic type B aortic dissection.
Methods
Study selection
An electronic search was performed using the Embase
and Medline databases from 1950 to January 2011. The
free-text and MeSH search terms “chronic,” “aortic,”
“dissection,” “aortic syndrome,” and “endovascular” were
used in combination with the Boolean operators AND or OR.
The reference lists of articles obtained were also searched
to identify further relevant citations. Finally, the search
included the Current Controlled Trials Register (www.
controlled-trials.com), the DARE database and the
Cochrane Database of Controlled Trials. The literature
review conformed to PRISMA statement standards.17,18
Quantitative meta-analysis was not performed due to the
heterogeneity of study design, treatment methodology and
patient population in studies that were included in quali-
tative review. The minimum inclusion criteria specified
data concerning early or mid-term mortality after TEVAR
for chronic type B dissection in 10 or more patients (Fig. 1).
Definitions
Chronic type B aortic dissection was defined by presentation
after 14 days of symptom onset. Technical success indicated
satisfactory closure of the primary entry tear, endograft
deployment without type I or III endoleak or the absence of
open surgical conversion or death within 24 h of the opera-
tion.19 ‘Early’ and ‘mid-term’ outcomes were defined
according to reporting criteria as within 30 days of operation,
andfrom30days to5yearsafter theoperation, respectively.19
Data extraction
Data were extracted regarding demographics, co-morbidity,
case selection (indication, maximum reported descending
aortic diameter, time from symptom onset, proportion of
symptomatic patients, true lumen:false lumen ratio, primary
entry tear location, number and location of fenestrations,
operative details, technical success, and early andmid-term
outcomes (endoleak, subsequent aortic expansion, retro-
grade dissection, aortic rupture, stroke, paraparesis or
paraplegia, 30-day and mid-term mortality, length of stay
and freedom from re-intervention). Data were collected by
two authors (ST and AK); discrepancies were resolved by
discussion with mutual consensus.
Results
The literature search identified 97 abstracts, of which 16
were excluded for reporting acute B-AD. 81 full-text arti-
cles were scrutinised. 26 were excluded for featuring lessthan 10 cases of chronic B-AD, 36 were excluded for
reporting a mixed cohort of acute B-AD and chronic B-AD
without data pertaining exclusively to treatment of chronic
B-AD, and 2 were review articles without original data.
Based on these entry and exclusion criteria, original data
from 17 articles were reviewed, which encompassed the
endovascular management of 567 patients described in 1
randomised controlled trial, 14 retrospective cohort studies
and 2 prospective cohort studies.2,4,5,7,20e32
Case selection
Patient demographics, presenting features and co-
morbidities are shown in Table 1. The mean age was 60
years; 82% were male and 40% initially presented symp-
tomatically. The most common co-morbidities were
hypertension (79.4%), coronary artery disease (20.6%), prior
aortic surgery (18.5%) and chronic respiratory impairment
(18.2%). 5.5% of all patients were reported as having the
Marfan syndrome. The median time from dissection to
intervention was 18 months (range 20 dayse129 months).
The most common stated indication for intervention was
a maximum descending aortic diameter exceeding 50 mm
(10/17, 58.8%). Eleven studies listed more than one indi-
cation for TEVAR but of these, only four studies listed the
proportions for each indication. Many studies predomi-
nantly reported the results of TEVAR in asymptomatic
patients with chronic B-AD (166/277, 59.9%). Other indi-
cations included rapid aortic enlargement (>10 mm/year),
proven or imminent aortic rupture, refractory chest pain,
refractory hypertension and end-organ ischaemia. No data
were available regarding the number and location of
fenestrations, pre-operative true lumen/false lumen ratio,
or the level at which maximum pre-operative descending
thoracic aortic diameter was reported.
Technical aspects and success
Procedural details and technical success rates are shown in
Table 2. The Talent stent-graft (Medtronic, Santa Rosa, CA,
USA) was the most common employed (10/17, 58.8%). A
median of 1.56 devices (range 1e3) were used per patient
with a graft lengths of 60e359 mm (median 131.7 mm). The
technical success rate was 89.9% (range 77.6e100), with
a median operating time 132.9 min (range 20e380). 4/17
studies reported that supra-aortic branch revascularisation
(e.g. carotid-subclavian bypass) was performed in 21.7% of
patients (28/129).
Early clinical success
‘Early’ clinical success was defined by outcomes within the
first 30 postoperative days (Table 3). The average duration
of intensive care and inpatient stay were 3.3 and 10 days
respectively. The overall 30-day mortality was 3.2% (18/
567). Endoleak was the commonest early complication
(11.7%, 38/325). In studies that reported endoleaks
according to subtype, the global incidence of endoleak was
15.8% (37/234), 15.4% (36/234) type I and 0.43% (1/234)
type II. The incidence of early retrograde dissection was
1.6% (3/187) and that for peri-procedural aortic rupture
Table 2 Technical aspects and Technical success.
Study N Stent-graft Number of
stent-grafts
per patient
Stent length (L);
diameter
(D) (mm)
Technical
success
Primary
conversion
Operation
time
(minutes)
Pre-procedural
preparation
Adjunctive
procedures
Xu 20102 84 Talent 33/84
(39.3%), Endofit
1/84 (1.2%),
Hercules 27/84
(32.1%), Vasoflow
3/84 (3.6%),
Grikin 20/84
(23.8%)
e e 77/84 (91.7%) 0 150  18 e LSA occlusion
4/84 (4.8%)
Czerny 20105 14 Talent, Valiant,
Relay
e L: 190 (100e250) 12/14 (85.7%) 0 e Supra-aortic
transposition
1/14 (7.1%)
e
Nienaber
20097
72 Talent 72/72
(100%)
1.34 (1e3) e 69/72 (95.8%) 0 108 (20e200) e Iliac artery stenting
1/72 (1.4%), aortic
stent-graft extension
1/72 (1.4%), aortic
bare-stent extension
1/72 (1.4%), LSA
occlusion 17/72
(23.6%), access-vessel
patch repair 1/72 (1.4%)
Manning
200920
10 Zenith 9/10 (90%),
Excluder
1/10 (10%)
e e 10/10 (100%) 0 e e Unilateral renal artery
stenting 2/10 (20%),
infrafrenal stent-graft
to treat AAA 1/10
(10%), coil embolization
of internal iliac artery
aneurysm 1/10 (10%)
Kim 20094 72 Custom-made
72/72 (100%)
e L: 83  27; D:
proximal 33.8  6.8,
distal 33.2  6.3
70/72 (97.2%) 1/72
(1.4%)
e e e
Guangqi
200921
49 Talent, Zenith,
Ankura, Aegis
1.08  0.34 e 38/49 (77.6%) 0 e e e
Alves 200922 61 Braile 61/61
(100%)
1.7  0.8 e 60/61 (98.4%) 2/61
(3.3%)
e LCCA-LSA bypass
14/61 (23.0%)
e
Sayer 200823 40 Valiant 22/40
(55.0%), Talent
16/40 (40.0%),
Excluder 3/40
(7.5%)
2.12 L: 204  20; D:
proximal 32.9  1.3,
distal 26.9  2
40/40 (100%) 0 133.5 C-C-LSA bypass
7/40 (17.5%),
LCCA-LSA bypass
4/40 (10.0%)
LCC occlusion
9/40 (22.5%)
(continued on next page)
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Table 2 (continued)
Study N Stent-graft
Number of
stent-grafts
per patient
Stent length (L);
diameter
(D) (mm)
Technical
success
Primary
conversion
Operation
time
(minutes)
Pre-procedural
preparation
Adjunctive
procedures
Marcheix
200824
15 1.5  0.7 (1e3) L: 135 (60e200) 15/15 (100%) 0 e e LSA occlusion 2/15
(13.3%)
Jing 200825 35 Talent 12/35
(34.3%), Zenith
2/35 (5.7%),
Aegis 21/35
(60.0%)
e L: 102.4  15.3;
D: 37.2  4.2
35/35 (100%) 0 139  25 e LSA occlusion 2/35
(5.7%)
Song 200626 17 Talent 15/17
(88.2%), AneuRx
2/17 (11.8%)
2.5  0.7 L: 188  61 (96e359);
D: 36.3  4.2
e 0 149.9  88.5 e LSA occlusion 4/17
(23.5%)
Bockler
200627
14 Excluder 11/14
(78.6%),
Talent 3/14
(21.4%),
Endofit 1/14 (7.1%)
1.2 (1e3) L: 169 (100e220);
D: 28e40
e 0 e LSA transposition
1/14 (7.1%),
C-LSA bypass
1/14 (7.1%)
LSA occlusion
5/14 (35.7%),
immediate LSA-LCCA
bypass 1/14 (7.1%)
Kusagawa
200528
17 Gianturco 17/17
(100%)
e e 17/17 (100%) 0 e e Spinal drainage
14/17 (82.4%)
Eggebrecht
200529
28 Talent 28/28
(100%)
1.2  0.5 (1e3) L: 100 (100e160); D:
37 (30e46)
28/28 (100%) 0 155  72
(45e380)
e LSA occlusion
4/28 (14.3%)
Shimono
200230
13 Gianturco 13/13
(100%)
1.4 (1e3) L: 81.9  16.7
(75e100); D: proximal
34.1  3.3 (30e42),
distal 31.9  3.1
(28e38)
13/13 (100%) 0 112  29
(75e155)
e LSA occlusion
1/13 (7.7%)
Kato 200231 14 Custom-made
14/14 (100%)
e L: 75 14/14 (100%) 0 e e e
Herold
200232
12 Talent 11/12
(91.7%), TAG
1/12 (8.3%)
e L: 120 12/12 (100%) 0 e e 0
Total 567 Talent 190/302 (62.9%), Valient
22/40 (55.0%), Zenith 11/45
(24.4%), Excluder 15/64 (23.4%),
Endofit 2/98 (2.0%), Hercules
27/84 (32.1%), Vasoflow 3/84
(3.6%), Grikin 20/84 (23.8%),
Aegis 21/35 (60.0%), Braile
61/61 (100%), AneuRx
2/17 (11.8%), Gianturco 30/30
(100%), TAG 1/12 (8.3%),
Custom-made 86/86 (100%),
Relay n/a, Ankura n/a
e e 510/567 3/567 e 28/129 71/357
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TEVAR for Chronic Type B Aortic Dissection 639was 2.3% (7/303). Neurological complications were rare;
the incidence of stroke was 0.82% (4/489), and the reported
incidence of paraplegia or paraparesis was 0.43% (2/462).Mid-term clinical success
Mid-term clinical success was defined by outcomes between
30 days and 5 years postoperatively (Table 4); no studies
provided outcome data beyond this point. The median
length of follow-up was 26.1 months (range 0.6e97), during
which the all studies used computed tomography angiog-
raphy (CTA) as their imaging modality of choice; with a few
studies additionally employing magnetic resonance angi-
ography (MRA) and trans-oesophageal echocardiography
(TOE). The late all-cause mortality rate was 9.2% (46/499).
Survival rates ranged from 59.1 to 100% in studies with
a median follow-up of 24 months (Fig. 2). The mid-term
aortic-related mortality was derived from those studies
that specifically reported it as 4.2% (18/425). Absolute re-
intervention rates ranged from 0 to 60% in studies with
a median follow-up of 31 months. Three cases of delayed
retrograde type A dissection were reported (0.67%),2,7,26 1
case of aorto-oesophageal fistula was reported (0.22%),29
and mid-term neurological complications were rare (para-
plegia 2/447, 0.45%; stroke 7/475, 1.5%). Mid-term health
economic data were not available.
The commonest delayed complication was the develop-
ment of aneurysms of the distal aorta or continued false
lumen perfusion with aneurysmal dilatation (26/332, 7.8%)
(Fig. 3). The mid-term incidence of endoleak was 8.1% (25/
309) (Fig. 4). In studies which reported endoleak according
to subtype, type I endoleak was most common and was
reported in 7.4% (23/309) of patients, compared to type II
and type III endoleak which were each reported in 0.3% (1/
309) of patients. Fewer studies reported subgroup defini-
tions of type I endoleak. In these reports, mid-term type I
endoleaks were predominantly proximal; the incidence of
type Ia endoleak was 5.2% [12/232] compared to 0.43% [1/
232] incidence of type Ib endoleak. Delayed aortic rupture
was reported in 3.0% (12/403). No studies reported whether
rupture occurred within or distal to the stented segment, or
following persistent false lumen perfusion.
Rates of complete false-lumen (FL) thrombosis ranged
from 38.5 to 100% (median 85.7%) in studies with a median
follow-up of 17 months2,4,5,7,20,21,23,24,26,28,30,32 and
appeared to have been reported in a bimodal manner
(Fig. 5). However, reporting was variable in completeness
and the total number of patients in which results were
available was low. Studies reporting mid-term follow-up of
the true lumen:false lumen ratio observed reduction in
false lumen diameter in 79.4% (27/34), FL expansion
occurred in 15% (9/60), and true lumen (TL) expansion in
66.1% (41/62) of patients followed-up for a median of
30 months.4,23,26,28,29 There was heterogeneity in the
manner in which changes in aortic diameter were reported,
with different numbers of studies reporting growth,
shrinkage or stasis in the maximum diameter of the thoracic
aorta. Although the denominator for each group was
therefore different, summary statistics revealed that
expansion in the overall maximum diameter of the thoracic
aorta was reported in 2.5% (1/40), reduction in the overall
Table 3 30-day clinical success.
Study N Length of
hospital
stay (days)
30-day Morbidity 30-day Mortality
Endoleak Retrograde
dissection
Rupture Stroke Paraparesis/
Paraplegia
System failure Miscellaneous
Xu 20102 84 mean
10  2.0
Type Ia
7/84 (8.3%)
e 4/84
(4.8%)
0 0 Renal 4/84 (4.8%) Fever>38 C 47/84 (56.0%),
back pain 52/84 (61.9%)
1/84 (1.2%)
Czerny 20105 14 e Type Ia
2/14 (14.3%)
0 0 0 0 0 0 0
Nienaber 20097 72 median 8
(5e29),
ITU 1
(0.5e5.3)
e Type A 1/72
(1.4%)
0 1/72
(1.4%)
2/72
(2.8%)
e e 2/72 (2.8%)
Manning 200920 10 e e e e 0 e e Stent-graft in coeliac trunk
compressed by FL 1/10 (10%)
0
Kim 20094 72 e Type I
18/72 (25%)
e e 0 0 Renal 1/72 (1.4%) Stent migration 2/72 (2.8%),
access site pseudoaneurysm
2/72 (2.8%)
0
Guangqi 200921 49 e Type I
5/49 (10.2%)
e 1/49
(2.0%)
1/49
(2.0%)
0 Cardiac 3/49
(6.1%), respiratory
1/49 (2.0%)
Pneumonia 3/49 (6.1%),
access complications 2/49
(4.1%), MI 1/49 (2.0%)
4/49 (8.2%)
Alves 200922 61 e e e e e e e e 2/61 (3.3%)
Sayer 200823 40 mean 11.9,
ITU 2.7
e Type A 1/40
(2.5%)
2/40
(5%)
0 0 e e 3/40 (7.5%)
Marcheix 200824 15 mean
14.4  13
Type I
4/15 (26.7%),
Type II
1/15 (6.7%)
e e 1/15
(6.7%)
0 e e 3/15 (20%)
Jing 200825 35 e 1/35 (2.9%) e e 0 0 Renal 1/35 (2.9%) Post-implantation syndrome
3/35 (8.6%), wound infection
1/35 (3.1%)
0
Song 200626 17 median
9.9  10.5,
ITU
6.4  10.4
e 1/17 (5.9%) e 1/17
(5.9%)
e Renal 1/17 (5.9%),
cardiac 2/17
(11.8%)
e 2/17 (11.8%)
Bockler 200627 14 e e e e 0 0 e e 0
Kusagawa 200528 17 e 0 0 0 e e e e 0
Eggebrecht 200529 28 median
13 (4e77),
ITU 3
(1e78)
e e e 0 0 e e 0
Shimono 200230 13 e 0 0 0 0 0 0 Wound infection 1/13 (7.7%) 0
Kato 200231 14 e 0 0 0 0 0 0 Wound infection 1/14 (7.1%) 0
Herold 200232 12 mean 2.8 0 e e 0 0 e MI 1/12 (8.3%) 1/12 (8.3%)
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TEVAR for Chronic Type B Aortic Dissection 641maximum thoracic aortic diameter in 17.6% (6/34) and no
change in the maximum thoracic aortic diameter was
reported in 12.5% (5/40) of patients.Discussion
Chronic type B dissection poses unique challenges to the
application of endovascular technology, yet the mid-term
outcomes of TEVAR remain ill defined. Thickening of the
dissection septum, which usually begins with symptom
onset, progresses with the chronicity of B-AD, and may be
less amenable to successful endografting than in the acute
phase. Consequently, chronic B-AD exhibits a lesser degree
of aortic remodelling than is seen in acute B-AD.23,28,33
False-lumen thrombosis is key to ensuring long-term clin-
ical success in chronic B-AD, which mandates extensive
aortic coverage.23 In the present review the length of
stent-grafts deployed varied widely, from 60 to 359 mm
(mean 131.7 mm). This diversity in aortic coverage,
alongside variation in case selection and reporting stan-
dards, may have contributed to the variation seen in mid-
term outcomes, which were heterogeneous.Early outcomes
The mean 30-day mortality after TEVAR for chronic B-AD in
the present study was 3.2%, which was similar to that
reported by Eggebrecht et al. in a comparative meta-
analysis demonstrating lower 30-day mortality after TEVAR
for chronic B-AD compared to TEVAR for acute B-AD (chronic
3.2% vs. acute 9.8%).13 The rate of early endoleak reported
after TEVAR for chronic B-AD in this series was 11.1%, which
was the most common early complication observed. Due to
the lack of recent controlled, comparative evidence for
open repair of chronic B-AD, the authors compared the
aggregate data of TEVAR from the present study with those
of open surgical series.34 This demonstrated benefits in
favour of TEVAR in terms of low in-hospital mortality (TEVAR
3.2% vs. open 9.6%), paraplegia (TEVAR 0.43% vs. open 4.8%)
and stroke (TEVAR 0.82% vs. open 5.8%). TEVAR resulted in
a low rate of postoperative renal insufficiency (TEVAR 2.6%
vs. open 4.8%), shorter length of stay in intensive care
(TEVAR 3 days vs. open 6.2 days) and a shorter overall
hospital stay (TEVAR 10 days vs. open 18.3 days). Although
the data were not randomised ormatched and selection bias
is likely, the early outcomes of TEVAR in chronic B-AD appear
encouraging. It must also be noted that nomid- or long-term
data currently exist for the open treatment of chronic B-AD;
such data is required for meaningful and direct comparison
of outcomes with TEVAR.Technical success and feasibility
The technical success rates reported for TEVAR were
reasonable, but remain lower than those reported previ-
ously in reviews of acute B-AD (chronic 89.9% vs. acute
95%).15 Others have noted no significant difference in the
rate of technical success after TEVAR for acute and chronic
B-AD (acute 93.4 0.9%, chronic 96.0 1.2%, pZ 0.381).13
Table 4 Mid-term clinical success.
Study N Length of
follow-up
(months)
Follow-up
imaging
modality
Endoleak after
30 days
(excluding
immediate
intra-operative
endoleaks)
Rupture
after
30 days
Retrograde
type A
dissection
after
30 days
Aneurysm of
distal aorta
or of false
lumen
Aorto-
oesophageal
or aorto-
bronchial
fistula
Paraplegia Stroke Freedom
from re-
intervention
or absolute
re-intervention
rate
Survival Overall Mortality False-lumen
thrombsis
Change in TL:FL
Ratio
Xu 20102 84 mean
33.2  19.2
(6e86)
CTA Type Ia 7/84
(8.3%)
5/84
(5.95%)
1/84
(1.19%)
1/84
(1.19%)
0 0 0 75% at
5 years,
4/84 (4.8%)
absolute
rate
84% at 5 rs All-cause 8/84
(9.5%), aorta-
related 4/84
(4.8%)
77/84
(91.6%)
complete,
7/84 (8.3%)
partial
e
Czerny
20105
14 median
34 (6e64)
CTA Type Ia 2/14
(14%)
1/14
(7.14%)
0 0 0 0 0 2/14
(4.2%)
absolute rate
e All-cause
3/14 (21%),
aorta-related
1/14 (7.1%)
12/14 (85.7%)
complete
e
Nienaber
20097
72 24 CTA/MRA e e 1/72
(1.4%)
7/72
(9.7%)
0 2/72
(2.8%)
2/72
(2.8%)
13/72
(18.1%)
absolute rate
88.9% at ears All-cause
8/72 (11.1%),
aorta-related
2/72 (2.8%)
63/69
(91.3%)
complete,
6/69 (8.7%)
partial
FL reduction
of 47%,
TL expansion
of 16%,
Maximal aortic
diameter
reduction at
2 years of 0.7%.
Before stenting
TL:FL Z 1:1.51,
after stenting
TL:FL Z 2.58:1
Manning
200920
10 mean 56,
median 64.5
(19e86.5)
CTA Type Ia
2/10 (20%)
0 0 1/10
(10%)
0 0 1/10
(10%)
6/10
absolute
rate (60%)
e 0 9/10 (90%)
complete
e
Type Ib 1/10
(10%)
Kim 20094 72 median 43,
mean
64.4  38.8
(5e97)
CTA Type I 6/72
(8.3%)
1/72
(1.4%)
0 9/72
(12.5%)
0 0 0 9/72
absolute
rate (12.5%)
98.3% at ears
(dissectio related)
All-cause
5/72 (6.9%),
aorta-related
1/71 (1.4%)
35/47 (74.5%)
complete,
12/47 (25.5%)
partial
9/60 (15%)
FL expansion
Guangqi
200921
49 mean
22.1  20.8
CTA e 0 0 e 0 0 0 e 64.7% at ears All-cause 10/49
(20.4%),
aorta-related
1/49 (2.0%)
20/40 (50%)
complete,
20/40 (50%)
partial
e
Alves 200922 61 mean
35.9  28.5
CTA e e e e e e e 10/45
(22%) absolute
late re-
intervention
rate
e All-cause 5/61
(8.2%)
e e
Sayer 200823 40 30 CTA Type Ia 1/40
(2.5%)
0 0 5/40
(12.5%)
0 0 0 62% at 30
months, 11/30
(36.7%)
absolute rate
66.5% at months e 40/40 (100%) descending
thoracic aorta:
1/40 (2.5%)
expansion,
5/40 (12.5%)
static
Type II 1/40
(2.5%)
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Marcheix
200824
15 mean
25.2  16.8
CTA/MRA Type I 4/15
(27%)
2/15
(13.3%)
0 e 0 0 1/15
(6.7%)
4/15
(26.7%)
absolute
late Re-
intervention
rate
e All-cause 3/15
(20%), aorta-
related 3/15 (20%)
12/14 (85.7%)
complete,
2/14 (14.3%)
partial
e
Type III
1/15 (6.7%)
Jing 200825 35 mean
17  14
CTA/MRA 0 0 0 e 0 0 0 e 96.2% at 4 years All-cause 1/35
(2.9%), aorta-
related 0/35 (0%)
e e
Song
200626
17 mean
11 (0.6e66)
CTA e e 1/17
(6%)
e 0 0 2/17
(12%)
1/17 (12%)
absolute late
Re-intervention
rate
e All-cause
4/17 (23.5%),
aorta-related
3/17 (17.6%)
17/17 (100%)
complete
At 1 year:
17/17 (100%)
FL reduction,
6/17 (35%) TL
expansion,
4/17 (22%)
reducing
aortic
diameter
Bockler
200627
14 Mean 24 CTA e e e 3/14
(21%)
e e e 80% at 1 year 72% at 5 years All-cause 2/14
(14.3%), aorta-
related 2/14
(14.3%)
e e
74% at 2 years
60% at 5 years
Kusagawa
200528
17 mean 43.2  18 CTA e 0 e e e e e No re-
intervention
100% at 2 years,
100% at 5 years
0 7/17 (41.2%)
complete,
7/17 (41.2%)
partial, 3/17
(17.6%) static
At 2 years:
10/17 (58%)
FL reduction,
7/17 (41%) TL
expansion
2/17 (12%)
reducing aortic
diameter
Before stenting
TL:FL Z 1: 1.21
After stenting
TL:FL Z 2.8 : 1
Eggebrecht
200529
28 median
18 (1e55)
CTA/MRA/
TOE
e 3/28 (9%) e e 1/28
(3%)
e 1/15 (6.7%) e 78.8% at 2 years e e 28/28 (100%)
TL expansion
59.1% at 4 years
Shimono
200230
13 mean
26.1  10
(8e40)
CTA 0 0 0 e e 0 0 No re-
intervention
e 0 5/13 (38.5%)
complete,
6/13 (46.2%)
partial, 2/13
(15.4%) static
e
Kato 200231 14 Mean 27 CTA 0 0 0 0 0 0 0 0/14 (0%)
absolute rate
e 0 e e
Herold 200232 12 Mean 8 CTA/MRA 0 0 0 0 0 0 0 1/12 (8.3%)
absolute rate
e All-cause 2/12
(16.7%)
12/12 (100%)
complete
e
Total 567 e e Overall 25/309,
type I 23/309
(type Ia 12/232,
type Ib 1/232),
type II 1/309,
type III 1/309
12/403 3/447 26/332 1/462 2/447 7/475 Absolute
rate 30/189
e All-cause
46/499, aorta-
related 18/425
- 27/34 (79.4%) FL
reduction,
9/60 (15%) FL
expansion,
41/62 (66.1%)
TL expansion
1/40 (2.5%)
(continued on next page)
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Figure 2 Scatterplot to illustrate mid-term survival after
TEVAR for chronic B-AD. Each of the 10 studies is represented
by a single datapoint. The sample size of each study (range
14e84) is reflected by the size of its respective datapoint. The
reference number of each study is also displayed within the
respective datapoint.
644 S.G. Thrumurthy et al.Mid-term outcomes
Although aneurysm-related mortality was not specifically
reported in many studies, mid-term aortic complications
were an important feature of TEVAR for chronic B-AD.
Previous reviews have suggested that up to 20% of patients
with chronic B-AD require re-intervention for established or
imminent rupture in the follow-up period after TEVAR with
optimal medical treatment.10 In the present review abso-
lute re-intervention rates were diverse, ranging from 0 to
60% in studies with a median follow-up of 31 months. The
commonest causes of delayed morbidity were aneurysmal
dilatation of the distal aorta or false lumen (26/332, 7.8%)
and mid-term endoleak (25/309, 8.1%), which appeared to
increase steadily during follow-up (Figs. 3 and 4).
The majority of endoleaks were proximal Type I, and
delayed aortic rupture was reported in 3.0% (12/403), but
no studies reported whether rupture occurred within or
distal to the stented segment, or following persistent falseFigure 3 Scatterplot to illustrate mid-term incidence of
distal aneurysmal expansion of the thoracic aorta after TEVAR
for chronic B-AD. Each of the 9 studies is represented by
a single datapoint. The sample size (range 10e84) of each
study is reflected by the size of its respective datapoint. The
reference number of each study is also displayed within the
respective datapoint.
Figure 4 Scatterplot to illustrate mid-term incidence of
endoleak after TEVAR for chronic type B aortic dissection. Each
of the 10 studies is represented by a single datapoint. The
sample size of each study (range 10e84) is reflected by the size
of its respective datapoint. The reference number of each
study is also displayed within the respective datapoint.
TEVAR for Chronic Type B Aortic Dissection 645lumen perfusion. The increased risk of rupture compared to
acute B-AD may be attributable to the decreased mobility
of the dissection flap over time, the greater likelihood of
consequent aneurysmal dilatation and the relative lack of
aortic remodelling in chronic B-AD compared to acute B-
AD.23,35 Ongoing surveillance is clearly critical to identify
such complications, although no studies have investigated
the optimal frequency and modality of surveillance.
Overall mid-term mortality was 9.2% (46/499), though
individual survival rates varied from 59.1 to 100% in studies
with a median follow-up of 24 months. The wide range of
survival rates reported in the literature (Fig. 2) may reflect
heterogeneity in case selection, unreported surgical turn-
down rates, small sample size within existing case series,
and the immature nature of the existing evidence base.
More robust and plentiful evidence is therefore needed to
establish the mid-term safety of TEVAR as an alternative to
open repair or best medical therapy, and to characterise
which patients derive the greatest benefit. Mid-term healthFigure 5 Scatterplot to illustrate mid-term incidence of
complete false-lumen thrombosis after TEVAR for chronic B-
AD. Each of the 12 studies is represented by a single datapoint.
The sample size of each study (range 14e84) is reflected by the
size of its respective datapoint. The reference number of each
study is also displayed within the respective datapoint.economic data were also not available to facilitate
comparison of TEVAR to open repair or conservative
management in chronic B-AD. All of the above must be put
in to context through the collection and publication of
accurate natural history data for aortic type B dissections.
It has been suggested that TEVAR is associated with
improved 1-year survival (TEVAR 90e93% vs. open 79e81%)
but poorer 3-year survival (TEVAR 67% vs. open 71%) than
open repair.12 In contrast, the INSTEAD trial reported no
survival advantage of TEVAR over best medical therapy at 2
years (medical therapy 95.6% vs. TEVAR 88.9%, p Z 0.15);
and no improvement in the rate of aortic rupture or the
need for endovascular or open re-intervention.7 However,
in favour of TEVAR, the trial demonstrated a significantly
greater degree of aortic remodelling after TEVAR (rate of
TL patency and FL thrombosis; TEVAR 91.3% vs. medical
therapy 19.4%, p < 0.001).36 These findings are supported
by the summary data from the present review, which
demonstrate FL reduction in 79.4% (27/34) and TL expan-
sion in 66.1% (41/62) of patients followed-up for a median
of 30 months. The median rate of complete FL thrombosis
in the literature was 85.7%, similar to the rate observed
after TEVAR for acute B-AD (85%),15 though individual
studies varied widely (Fig. 5).
Although reporting standards have been agreed for
endoleak in the context of aneurysmal disease,19 it has
been widely acknowledged that definitions of endoleak
from aneurysm reporting criteria are not fully applicable to
dissections.37 Various definitions of type I endoleak were
used in reports of TEVAR for chronic B-AD. Some authors
defined endoleak as any radiological evidence of flow
outside the stent-graft except persistent retrograde FL
perfusion,27 others as flow into the FL due to an ineffective
seal at one extremity of the stent-graft,21 and others as any
failure of entry tear closure resulting in continued ante-
grade FL perfusion.5 Consensus reporting criteria are
required to account for situations unique to dissection such
as FL perfusion arising from the left subclavian artery
despite an adequate proximal endograft seal, or a persis-
tently patent FL distal to the endograft despite a throm-
bosed FL at the level of the endograft.37
Despite a large number of published cohort studies for
TEVAR in chronic B-AD, few data were available to assess
outcomes up to 5 years. The wide range observed in
mortality, re-intervention and major complications reflec-
ted the paucity of mid-term data available specifically for
TEVAR in chronic B-AD. Reports of long-term results from
sources such as the ongoing VIRTUE Registry38 of Type B
thoracic dissections are needed in the world literature to
improve our understanding of the treatment of these
pathologies.
The potential methodological limitations of this study
include the inability to eliminate selection bias from the
review. This was due to the vast majority of key papers
being retrospective case series, in which the proportions of
rejected cases were often not reported.39 Nevertheless,
trends in selection towards age, gender and patient co-
morbidities were available for summary. Other variations in
case reporting (e.g. inconsistent reporting of proportions of
indications for TEVAR) also limited further stratification of
treatment outcomes. Similarly, the issue of information
bias cannot completely be overcome at this stage, as it is
646 S.G. Thrumurthy et al.too early to estimate the proportion of poor TEVAR results
that are not published. This is a typical concern of any of
such new technology, and provides another incentive for
randomised controlled trials of TEVAR in chronic B-AD.
Conclusion
Current evidence demonstrates conflicting outcomes for
the use of TEVAR over best medical therapy and open
repair for chronic B-AD. The lack of natural history data
for cases treated medically or by open repair, significant
heterogeneity in case selection and absence of consensus
reporting standards for intervention are significant
obstructions to interpreting these data, and making
robust comparisons of TEVAR against open repair or best
medical treatment. Future case series, registries and
clinical trials must address each of these aspects in order
that we do not do patients a disservice. Mid- to long-term
outcome data (e.g. freedom from rupture, aneurysm
formation and re-intervention) must be a focus of such
studies. High-quality randomised studies are urgently
needed.
Funding
None required.
Conflict of Interest
None declared.
References
1 Czerny M, Zimpfer D, Rodler S, Funovics M, Dorfmeister M,
Schoder M, et al. Endovascular stent-graft placement of
aneurysms involving the descending aorta originating from
chronic type B dissections. Ann Thorac Surg 2007;83(5):
1635e9.
2 Xu SD, Huang FJ, Yang JF, Li ZZ, Yang S, Du JH, et al. Early and
midterm results of thoracic endovascular aortic repair of
chronic type B aortic dissection. J Thorac Cardiovasc Surg 2010;
139(6):1548e53.
3 Parsa CJ, Schroder JN, Daneshmand MA, McCann RL, Hughes GC.
Midterm results for endovascular repair of complicated acute
and chronic type B aortic dissection. Ann Thorac Surg 2010;
89(1):97e104.
4 Kim U, Hong SJ, Kim J, Kim JS, Ko YG, Choi D, et al. Interme-
diate to long-term outcomes of endoluminal stent-graft repair
in patients with chronic type B aortic dissection. J Endovasc
Ther 2009;16(1):42e7.
5 Czerny M, Roedler S, Fakhimi S, Sodeck G, Funovics M,
Dumfarth J, et al. Midterm results of thoracic endovascular
aortic repair in patients with aneurysms involving the
descending aorta originating from chronic type B dissections.
Ann Thorac Surg 2010;90(1):90e4.
6 Svensson LG, Kouchoukos NT, Miller DC, Bavaria JE, Coselli JS,
Curi MA, et al. Expert consensus document on the treatment of
descending thoracic aortic disease using endovascular stent-
grafts. Ann Thorac Surg 2008;85(1 Suppl.):S1e41.
7 Nienaber CA, Rousseau H, Eggebrecht H, Kische S, Fattori R,
Rehders TC, et al. Randomized comparison of strategies for
type B aortic dissection: the INvestigation of STEnt grafts inaortic dissection (INSTEAD) trial. Circulation 2009;120(25):
2519e28.
8 Nordon IM, Hinchliffe RJ, Loftus IM, Morgan RA, Thompson MM.
Management of acute aortic syndrome and chronic aortic
dissection. Cardiovasc Intervent Radiol; 2010.
9 Sueyoshi E, Sakamoto I, Hayashi K, Yamaguchi T, Imada T.
Growth rate of aortic diameter in patients with type B aortic
dissection during the chronic phase. Circulation 2004;110(11
Suppl. 1):II256e61.
10 Nordon IM, Yates MT, Hinchliffe RJ, Holt PJ, Loftus IM,
Thompson MM. Endovascular treatment of chronic aortic
dissection. Acta Chir Belg 2009;109(4):450e7.
11 Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS,
et al. Yearly rupture or dissection rates for thoracic aortic
aneurysms: simple prediction based on size. Ann Thorac Surg
2002;73(1):17e27. discussion 27e8.
12 Subramanian S, Roselli EE. Thoracic aortic dissection: long-term
results of endovascular and open repair. Semin Vasc Surg 2009;
22(2):61e8.
13 Eggebrecht H, Nienaber CA, Neuhauser M, Baumgart D,
Kische S, Schmermund A, et al. Endovascular stent-graft
placement in aortic dissection: a meta-analysis. Eur Heart J
2006;27(4):489e98.
14 Fattori R, Lovato L, Buttazzi K, Russo V. Evolving experience of
percutaneous management of type B aortic dissection. Eur J
Vasc Endovasc Surg 2006;31(2):115e22.
15 Parker JD, Golledge J. Outcome of endovascular treatment of
acute type B aortic dissection. Ann Thorac Surg 2008;86(5):
1707e12.
16 Nordon IM, Hinchliffe RJ, Holt PJ, Morgan R, Jahangiri M,
Loftus IM, et al. Endovascular management of chronic aortic
dissection in patients with Marfan syndrome. J Vasc Surg 2009;
50(5):987e91.
17 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA
statement. BMJ 2009;339:b2535.
18 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC,
Ioannidis JP, et al. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
healthcare interventions: explanation and elaboration. BMJ
2009;339:b2700.
19 Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Reporting standards for endovascular aortic
aneurysm repair. J Vasc Surg 2002;35(5):1048e60.
20 Manning BJ, Dias N, Ohrlander T, Malina M, Sonesson B, Resch T,
et al. Endovascular treatment for chronic type B dissection:
limitations of short stent-grafts revealed at midterm follow-up.
J Endovasc Ther 2009;16(5):590e7.
21 Guangqi C, Xiaoxi L, Wei C, Songqi L, Chen Y, Zilun L, et al.
Endovascular repair of stanford type B aortic dissection: early
and mid-term outcomes of 121 cases. Eur J Vasc Endovasc Surg
2009;38(4):422e6.
22 Alves CMR, da Fonseca JHP, de Souza JAM, Kim HC, Esher G,
Buffolo E. Endovascular treatment of type B aortic dissection:
the challenge of late success. Ann Thorac Surg 2009;87(5):
1360e5.
23 Sayer D, Bratby M, Brooks M, Loftus I, Morgan R, Thompson M.
Aortic morphology following endovascular repair of acute and
chronic type B aortic dissection: implications for management.
Eur J Vasc Endovasc Surg 2008;36(5):522e9.
24 Marcheix B, Rousseau H, Bongard V, Heijmen RH, Nienaber CA,
Ehrlich M, et al. Stent grafting of dissected descending aorta in
patients with Marfan’s syndrome. mid-term results. JACC Car-
diovasc Interv 2008;1(6):673e80.
25 Jing QM, Han YL, Wang XZ, Deng J, Luan B, Jin HX, et al.
Endovascular stent-grafts for acute and chronic type B aortic
dissection: comparison of clinical outcomes. Chin Med J 2008;
121(22):2213e7.
TEVAR for Chronic Type B Aortic Dissection 64726 Song TK, Donayre CE, Walot I, Kopchok GE, Litwinski RA,
Lippmann M, et al. Endograft exclusion of acute and chronic
descending thoracic aortic dissections. J Vasc Surg 2006;43(2):
247e58.
27 Bockler D, Schumacher H, Ganten M, von Tengg-Kobligk H,
Schwarzbach M, Fink C, et al. Complications after endovascular
repair of acute symptomatic and chronic expanding Stanford
type B aortic dissections. J Thorac Cardiovasc Surg 2006;132(2):
361e8. e4.
28 Kusagawa H, Shimono T, Ishida M, Suzuki T, Yasuda F, Yuasa U,
et al. Changes in false lumen after transluminal stent-graft
placement in aortic dissections: six years’ experience. Circu-
lation 2005;111(22):2951e7.
29 Eggebrecht H, Herold U, Kuhnt O, Schmermund A, Bartel T,
Martini S, et al. Endovascular stent-graft treatment of aortic
dissection: determinants of post-interventional outcome. Eur
Heart J 2005;26(5):489e97.
30 Shimono T, Kato N, Yasuda F, Suzuki T, Yuasa U, Onoda K, et al.
Transluminal stent-graft placements for the treatments of
acute onset and chronic aortic dissections. Circulation 2002;
106(12 Suppl. 1):I241e7.
31 Kato N, Shimono T, Hirano T, Suzuki T, Ishida M, Sakuma H, et al.
Midterm results of stent-graft repair of acute and chronic aortic
dissection with descending tear: the complication-specific
approach. J Thorac Cardiovasc Surg 2002;124(2):306e12.
32 Herold U, Piotrowski J, Baumgart D, Eggebrecht H, Erbel R,
Jakob H. Endoluminal stent graft repair for acute and chronic
type B aortic dissection and atherosclerotic aneurysm of the
thoracic aorta: an interdisciplinary task. Eur J Cardiothorac
Surg 2002;22(6):891e7.33 Resch TA, Delle M, Falkenberg M, Ivancev K, Konrad P, Larzon T,
et al. Remodeling of the thoracic aorta after stent grafting of
type B dissection: a Swedish multicenter study. J Cardiovasc
Surg 2006;47(5):503e8.
34 Zoli S, Etz CD, Roder F, Mueller CS, Brenner RM, Bodian CA,
et al. Long-term survival after open repair of chronic distal
aortic dissection. Ann Thorac Surg 2010;89(5):1458e66.
35 Rodriguez JA, Olsen DM, Lucas L, Wheatley G, Ramaiah V,
Diethrich EB. Aortic remodeling after endografting of thor-
acoabdominal aortic dissection. J Vasc Surg 2008;47(6):
1188e94.
36 Nienaber CA, Kische S, Akin I, Rousseau H, Eggebrecht H,
Fattori R, et al. Strategies for subacute/chronic type B aortic
dissection: the Investigation of Stent Grafts in Patients with
type B Aortic Dissection (INSTEAD) trial 1-year outcome. J
Thorac Cardiovasc Surg 2010;140(6 Suppl.):S101e8. discussion
S42eS46.
37 Haulon S. Comments regarding “Endovascular repair of Stanford
type B aortic dissection: early and mid-term outcomes of 121
cases” by Chang Guangqi, Li Xiaoxi, Chen Wei, Li Songqi, Yao
Chen, Li Zilun, Wang Shenming. Eur J Vasc Endovasc Surg 2009;
38(4):427e8.
38 The Virtue Registry I. The VIRTUE Registry of type B thoracic
dissections e study design and early results. Eur J Vasc Endo-
vasc Surg; 2010.
39 Karthikesalingam A, Nicoli TK, Holt PJ, Hinchliffe RJ, Pasha N,
Loftus IM, et al. The Fate of Patients Referred to a Specialist
Vascular Unit with Large Infra-renal Abdominal Aortic Aneu-
rysms over a Two-year Period. Eur J Vasc Endovasc Surg 2011;
42:295e301.
